0000-0001-9454-1382

Daniel joined the Nuffield Department of Clinical Neurosciences as Clinical Project Manager of the national ALS/MND C9orf72 Cohort study ('ACORN') in October 2022, tasked with establishing a national register of motor neuron disease patients and asymptomatic family members carrying the C9orf72 gene expansion. This register will be pivotal in supporting the development of therapeutic strategies and neurochemical biomarkers for ALS/MND. Daniel also manages the Oxford GENFI 3 study, focused on genetic factors leading to Frontotemporal dementia (FTD).  

Daniel has worked at the University of Oxford for five years, previously working in the Primary Care Clinical Trials Unit, and in Tropical Medicine and Global Health, where he managed the ISARIC data platform during the COVID pandemic, collecting and reporting on acute clinical COVID data from 62 countries.   

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.

Docherty AB, Harrison EM et al  British Medical Journal (BMJ) 2020 May 22    https://doi.org/10.1136/bmj.m1985

What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol.

Sigfrid L et al   British Medical Journal (BMJ) Open. 2021 Mar 10;11(3):e043887. PMID: 33692181

Global outbreak research: harmony not hegemony.

ISARIC clinical characterisation group. The Lancet Infect Dis. 2020 Jul;20(7):770-772. Epub 2020 Jun 2.

PMID: 32502433

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

Thomas M Drake et al. The Lancet (2021)   https://doi.org/10.1016/S0140-6736(21)00799-6